We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Out in the open.
- Abstract
The article informs that until recently, biotech and pharmaceutical companies have had little reason to heed calls for greater transparency in the disclosure data from their clinical trials. That all changed last year when New York State attorney general Eliot Spitzer filed a high-profile lawsuit against GlaxoSmithKline PLC alleging that the company had withheld trial data indicating that its antidepressant Seroxat (paroxetine) increased the risk of suicide in children. For some reason, the data revealing increased suicide risk were mysteriously absent from official GlaxoSmithKline summaries of Seroxat's clinical performance.
- Subjects
CLINICAL trials; GLAXOSMITHKLINE; ANTIDEPRESSANTS; CLINICAL medicine; DRUG laws; PHARMACEUTICAL industry
- Publication
Nature Biotechnology, 2005, Vol 23, Issue 2, p153
- ISSN
1087-0156
- Publication type
Editorial
- DOI
10.1038/nbt0205-153